NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
The company had earlier announced about the approval received from the MHRA for Liraglutide
Yesafili, received marketing authorization approval from the European Commission for the European Union
This approval has come from the company's finished dosage form manufacturing facility
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
Lutio has the potential to offer significant cost savings when available to UK patients.
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)